ORGANOVO HOLDINGS, INC. (NASDAQ:ONVO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.07 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 24, 2017, Keith Murphy submitted his resignation from the Board of Directors (the “Board”) of Organovo Holdings, Inc. (the “Company”), and from his service as Chairman of the Board.Mr. Murphy confirmed that his resignation was not due to any disagreements with the Company. Mr. Murphy shared with the Board that he has formed a new company that intends to be a potential customer of Organovo, and that he needed to step down from the Board in order to avoid conflicts of interest.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its Annual Meeting of Stockholders on August 24, 2017 (the “Annual Meeting”).Of the 105,627,542 shares of the Company’s common stock outstanding as of the record date, 75,519,538 shares, or 71.5%, were represented at the Annual Meeting either in person or by proxy.

In accordance with the Company’s Bylaws, the presence of the holders of at least a majority of the outstanding shares of common stock at the Annual Meeting, whether in person or by proxy, constituted a quorum for the transaction of business at the Annual Meeting.Votes “For,” “Withheld,” “Against,” “Abstentions” and “Broker Non-Votes” were each counted as present at the Annual Meeting for purposes of determining the presence of a quorum. Broker Non-Votes are shares held in street name by brokers, banks or other nominees who were present in person or represented by proxy at the Annual Meeting, but which were not voted on a proposal because the brokers, banks or nominees did not have discretionary authority with respect to that proposal and they had not received voting instructions from the beneficial owner prior to the Annual Meeting.Under the Company’s Bylaws, the Class III directors are elected by a plurality of the votes cast in person or by proxy at the Annual Meeting, which means that the three director nominees who received the highest number of “For” votes was elected.Approval of Proposals 2 and 3 each required the affirmative vote of a majority of the votes cast in person or by proxy at the Annual Meeting. Abstentions and Broker Non-Votes are not considered to be votes cast under the Company’s Bylaws, and as a result, have no effect on the outcome of the vote on any of the proposals.

A description of each matter voted upon at the Annual Meeting is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on July 14, 2017. The number of votes cast “For” and “Withheld” and “Against” and the number of “Abstentions” and “Broker Non-Votes” with respect to each matter voted upon are set forth below.

(1) Election of Directors.The Company’s stockholders elected Roberta Baltera Jr, James Glover and Richard Maroun, as a Class III directors, with the approval of 96.8% and 96.9% and 97.0% of the votes cast, to hold office until the 2020 Annual Meeting of Stockholders and until their respective successors are elected and qualified. The following table shows the tabulation of the votes cast For and Withheld for the election of each of the director nominees as well as the Broker Non-Votes submitted for each of the director nominees:

(2) Ratification of Auditors.The Company’s stockholders ratified the appointment of Mayer Hoffman McCann P.C., with the approval of 97.9% of the votes cast, as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2018. The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions submitted on this proposal:

(3) Executive Compensation.The Company’s stockholders, on a non-binding, advisory basis, approved the compensation of the Company’s named executive officers as disclosed in the proxy statement, with the approval of 93.3% of the votes cast.The following table shows the tabulation of the votes cast For and Against this proposal as well as the Abstentions and Broker Non-Votes submitted on this proposal:

No other items were presented for stockholder approval at the Annual Meeting.

About ORGANOVO HOLDINGS, INC. (NASDAQ:ONVO)

Organovo Holdings, Inc. is an early commercial-stage company focused on developing and commercializing functional human tissues. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D. It is focused on development of products, including 3D human tissues used for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion (ADME), and drug metabolism and pharmacokinetics (DMPK); customized human tissues as living, dynamic models of human biology or disease, for use in drug discovery and development, and three-dimensional human tissues for clinical applications, such as blood vessels for bypass grafting, nerve grafts for nerve damage repair and functional tissue patches for the repair or replacement of damaged tissues and organs.